TJ003234

anti-GM-CSF monoclonal antibody · I-Mab Biopharma US Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TJ003234, covering 2023-05-06 to 2023-05-06. Get the full timeline:

Most recent: Clinical Trial Update: Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) [Phase 2, Phase 3]

See pricing